Guardant360® Tissue—Maximum insights. Minimal tissue.
The most advanced multiomic tissue test that delivers DNA, RNA, and epigenomic insights—all with the lowest sample requirements.*1
Overview
Key features for Guardant360 Tissue
and is guideline-complete across all advanced solid tumors.
with 3 splice isoforms: MET, AR, EGFR.
including 47 promoter methylation genes.
6 slides for Guardant360 Tissue‡ vs 10-slide industry standard.
11-day turnaround time.†2
Covered by Medicare for all advanced solid tumors and is New York State approved.
Full suite of IHC available as an add-on.
Leading tests start with leading tech.
Now powered by the same technology behind the #1 liquid biopsy,3 Guardant360 Tissue taps into multiomic insights that deliver the most complete view of cancer, today and in the future.
Biomarker Panel
Guardant360 Tissue is guideline-complete across all advanced solid tumors.1,4-7
Covered guideline-recommended biomarkers for common cancer types:
ALK, BRAF, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3, RET, ROS1
AKT1, BRCA1, BRCA2, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, PALB2, PIK3CA, PTEN, RET, MSI, TMB
BRAF, ERBB2, KRAS, NRAS, NTRK1, NTRK2, NTRK3, POLD1, POLE, RET, MSI
ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MLH1, MRE11, NBN, PALB2, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, TP53, MSI, TMB
See the full panel.
The ultimate power behind cancer testing.
See more now
with multi-dimensional insights.
Do more today
with additional treatment options.
Discover more tomorrow
with continuous innovations.
Guardant tests§ are covered by all major insurers, including Aetna, Anthem, Cigna, United Healthcare, and others, ensuring access for 300 million+ lives.
Important note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
DNA, deoxyribonucleic acid; RNA, ribonucleic acid; IHC, immunohistochemistry
* Compared to other leading comprehensive tissue tests. The “most advanced” referring to the first and only commercially available tissue test to deliver multiomic insights from a single input.
† Median turnaround time from sample receipt to results.
‡ For NGS testing only.
§ Refers to Guardant360/Guardant360 CDx liquid biopsy.
For a full list of diagnoses, download the Controlled Language for Diagnosis page.
References: 1. Guardant360 Tissue™ Assay Specifications. Guardant Health, Inc. Redwood City, CA. 2. Guardant Health data on file. April 2025. Guardant Health, Inc. Redwood City, CA. 3. Guardant Health Data on File. Brand Tracker. 2024 4. Riely GJ, Wood DE, Ettinger DS, et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 5.2024, NCCN clinical practice guidelines in oncology. Accessed July 17, 2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf 5. Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 2.2024, NCCN clinical practice guidelines in oncology. Accessed July 17, 2024. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf 6. Benson AB, Venook AP, Adam M, et al. NCCN Guidelines® Insights: Colon Cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. Accessed July 17, 2024. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf 7. Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 4.2024, NCCN clinical practice guidelines in oncology. Accessed July 17, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf